BCR and B-cell chronic lymphocytic leukemia: In TCL1-driven CLL, the potent oncogene TCL1, coupled with an autoreactive BCR recognizing phosphatidylcholine or other autoantigens, is sufficient to initiate and drive aggressive disease progression, independent of additional autoimmune-derived environmental stimuli.